ATX
AMPLIA THERAPEUTICS ORDINARYAmplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
ATX
ATX
AMPLIA THERAPEUTICS ORDINARY
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer.
Fundamentals
Historical Data63 days
| Date | Short % | Gross Short |
|---|---|---|
| 28 Aug | — | — |
| 27 Aug | — | — |
| 26 Aug | — | — |
| 25 Aug | 0.01% | — |
| 24 Aug | 0.01% | — |
| 21 Aug | 0.01% | — |
| 20 Aug | 0.01% | — |
| 19 Aug | 0.01% | — |
| 18 Aug | 0.01% | — |
| 17 Aug | 0.01% | — |
| 14 Aug | 0.01% | — |
| 13 Aug | 0.01% | — |
Amplia Therapeutics (ATX) Short Interest Summary
Amplia Therapeutics (ATX) currently has 0.01% of its shares sold short (30 thousand shares, worth approximately $4K), based on ASIC short position data reported on 25 August 2026 (T+4 reporting lag). That makes ATX the #593 most shorted stock on the ASX most shorted list. Short interest in ATX is up 0.00% over the past week and down 0.01% over the past month. ATX is part of the Health Care sector on the ASX.
Recent ATX Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 25 Aug 2026 | 0.01% | 0.0M | $0.14 |
| 24 Aug 2026 | 0.01% | 0.0M | $0.15 |
| 21 Aug 2026 | 0.01% | 0.0M | $0.15 |
| 20 Aug 2026 | 0.01% | 0.0M | $0.15 |
| 19 Aug 2026 | 0.01% | 0.0M | $0.14 |
| 18 Aug 2026 | 0.01% | 0.0M | $0.16 |
| 17 Aug 2026 | 0.01% | 0.0M | $0.16 |
| 14 Aug 2026 | 0.01% | 0.0M | $0.14 |
| 13 Aug 2026 | 0.01% | 0.0M | $0.14 |
| 12 Aug 2026 | 0.01% | 0.0M | $0.14 |
ATX Short Selling — Frequently Asked Questions
What is Amplia Therapeutics (ATX)'s current short interest?
Amplia Therapeutics (ATX) currently has a short interest of 0.01% of total shares outstanding. This means 0.01% of ATX's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is ATX heavily shorted on the ASX?
ATX has a relatively low short interest of 0.01%. Short interest below 5% generally suggests limited bearish sentiment from short sellers.
What does short interest mean for ATX investors?
Short interest in ATX shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 0.01%, ATX's short interest is at a low level. See our short squeeze candidates and days to cover analysis for more context.
Where does this ATX short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for ATX.